Penn's Long Term Relationship with The Leukemia & Lymphoma Society Laid Groundwork for Transformative Therapies for Cancer Patients
Friday, December 7, 2012 - 17:01
in Health & Medicine
In August, The University of Pennsylvania(Penn) announced a major new strategic alliance with a major pharmaceutical company to further develop novel immunotherapies using chimeric antigen receptor (CAR) technology developed in the laboratories of Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine at Perelman School of Medicine and director of Translational Research in the Abramson Cancer Center. Penn recognizes the major role played by The Leukemia & Lymphoma Society (LLS) in enabling these discoveries to be developed and tested in patients to the point that Penn was able to attract a commercial partner.